CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Martel, Cyril Jean Marie ^a   Agger, Else Marie ^b   Poulsen, Julie Juul ^a   Jensen, Trine Hammer ^a   Andresen, Lars ^a   Christensen, Dennis ^b   Nielsen, Lars Peter ^b   Blixenkrone Møller, Merete ^a   Andersen, Peter ^b   Aasted, Bent ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC ADJUVANT FORMULATION 01; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; SQUALENE; UNCLASSIFIED DRUG; INACTIVATED VACCINE; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; FEMALE; FERRET; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LYMPHOCYTE; NONHUMAN; PROTEIN EXPRESSION; VIRUS LOAD; ACTIVE IMMUNIZATION; ANIMAL; IMMUNOLOGY; PATHOGENICITY;

MUSTELA; TIPULA IRIDESCENT VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; FERRETS; IMMUNITY, ACTIVE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LIPOSOMES; VACCINES, INACTIVATED;

EID: 79961136140     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022891     Document Type: Article

References (51)

1. Korsman S, eds. (2006) Vaccines. Influenza Report.: Flying Publisher.
2. Boni MF, (2008) Vaccination and antigenic drift in influenza. Vaccine 26: C8-C14.
3. Tambyah PA, (2008) Update on influenza vaccines. Respirology 13: S41-S43.
4. Orenstein WA, Schaffner W, (2008) Lessons Learned: Role of Influenza Vaccine Production, Distribution, Supply, and Demand-What It Means for the Provider. The American journal of medicine 121: S22-S27.
5. Gerdil C, (2003) The annual production cycle for influenza vaccine. Vaccine 21: 1776-1779.
6. Wood JM, (2002) Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20: B40-B44.
7. Fedson DS, (2008) NEW technologies for meeting the global demand for pandemic influenza vaccines. Biologicals 36: 346-349.
8. US Department of Health and Human Services (2005) HHS Pandemic Influenza Plan.
9. Sant AJ, Chaves FA, Krafcik FR, Lazarski CA, Menges P, et al. (2007) Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Review of Vaccines 6: 357-368.
10. Cox RJ, Brokstad KA, Ogra P, (2004) Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines. Scandinavian Journal of Immunology 59: 1-15.
11. Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, (2007) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Current Opinion in Biotechnology 18: 529-536.
12. Subbarao K, Joseph T, (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7: 267-278.
13. Mullbacher A, (1994) The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen. J Exp Med 179: 317-321.
14. Tamura S, Kurata T, (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57: 236-247.
15. Mann JFS, Shakir E, Carter KC, Mullen AB, Alexander J, et al. (2009) Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27: 3643-3649.
16. Launay O, Grabar S, Bloch F, Desaint C, Jegou D, et al. (2008) Effect of sublingual administration of interferon-[alpha] on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 26: 4073-4079.
17. Mann JF, Acevedo R, Campo Jd, Pérez O, Ferro VA, (2009) Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Review of Vaccines 8: 103-112.
18. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R, (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Research 103: 163-171.
19. Gupta RK, (1998) Aluminum compounds as vaccine adjuvants. Advanced Drug Delivery Reviews 32: 155-172.
20. Bungener L, Geeraedts F, ter Veer W, Medema J, Wilschut J, et al. (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359.
21. Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
22. Jones T, (2009) GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection. Curr Opin Mol Ther 11: 337-345.
23. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, et al. (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26: 552-561.
24. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements. PLoS ONE 3: e3116.
25. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-A novel adjuvant inducing both strong CMI and antibody responses. Biochimica et Biophysica Acta (BBA)- Biomembranes 1718: 22-31.
26. Martel CJ-M, Aasted B, (2009) Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. Veterinary Immunology and Immunopathology 132: 109-115.
27. European Medicines Agency (2009) Prepandrix European Public Assessment Report Summary.
28. Pinnamaneni S, Das NG, Das SK, (2003) Comparison of oil-in-water emulsions manufactured by microfluidization and homogenization. Pharmazie 58: 554-558.
29. Pedersen LG, Castelruiz Y, Jacobsen S, Aasted B, (2002) Identification of monoclonal antibodies that cross-react with cytokines from different animal species. Veterinary Immunology and Immunopathology 88: 111-122.
30. Aasted B, Viuff B, (2007) Reactivity of monoclonal antibodies to human CD antigens with cells from mink. Veterinary Immunology and Immunopathology 119: 27-37.
31. WHOResponse CDSa, editor (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance. In:.
32. Doherty PC, Christensen JP, (2000) Accessing Complexity: The Dynamics of Virus-Specific T Cell Responses. Annual Review of Immunology 18: 561-592.
33. Mukherjee S, Maiti PK, Nandi D, (2002) Role of CD80, CD86, and CTLA4 on mouse CD4+ T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. Journal of Leukocyte Biology 72: 921-931.
34. Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM, (1985) Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313: 318-320.
35. Hinshaw VS, Webster RG, Easterday BC, Bean WJ Jr, (1981) Replication of avian influenza A viruses in mammals. Infect Immun 34: 354-361.
36. Doherty PC, Turner SJ, Webby RG, Thomas PG, (2006) Influenza and the challenge for immunology. Nat Immunol 7: 449-455.
37. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC, (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
38. Ellebedy AH, Fabrizio TP, Kayali G, Oguin TH III, Brown SA, et al. (2010) Contemporary Seasonal Influenza A (H1N1) Virus Infection Primes for a More Robust Response To Split Inactivated Pandemic Influenza A (H1N1) Virus Vaccination in Ferrets. Clin Vaccine Immunol 17: 1998-2006.
39. Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, et al. (2011) Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine In Press, Corrected Proof.
40. Bodewes R, Kreijtz JHCM, Geelhoed-Mieras MM, van Amerongen G, Verburgh RJ, et al. (2011) Vaccination against Seasonal Influenza A/H3N2 Virus Reduces the Induction of Heterosubtypic Immunity against Influenza A/H5N1 Virus Infection in Ferrets. J Virol 85: 2695-2702.
41. Guo H, Kumar P, Malarkannan S, (2011) Evasion of natural killer cells by influenza virus. Journal of Leukocyte Biology 89: 189-194.
42. Long BR, Michaelsson J, Loo CP, Ballan WM, Vu B-AN, et al. (2008) Elevated Frequency of Gamma Interferon-Producing NK Cells in Healthy Adults Vaccinated against Influenza Virus. Clin Vaccine Immunol 15: 120-130.
43. Coates DM, Sweet C, Smith H, (1986) Severity of Fever in Influenza: Differential Pyrogenicity in Ferrets Exhibited by H1N1 and H3N2 Strains of Differing Virulence. J Gen Virol 67: 419-425.
44. Reuman PD, Keely S, Schiff GM, (1989) Assessment of signs of influenza illness in the ferret model. Journal of Virological Methods 24: 27-34.
45. Stebbing N, Healey GF, Round EM, (1982) The inadequacy of rectal temperature measurements for assessing the effects of antiviral drugs on influenza virus infection of ferrets. J Virol Methods 5: 343-350.
46. Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, et al. (2009) Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. Journal of virology 83: 3843-3851.
47. Smith Korsholm K, Agger EM, Foged C, Christensen D, Dietrich J, et al. (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121: 216-226.
48. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, et al. (2010) Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. Journal of Controlled Release 142: 180-186.
49. Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, et al. (2009) Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells. The Journal of Immunology 182: 8047-8055.
50. Werninghaus K, Babiak A, Groß O, Hölscher C, Dietrich H, et al. (2009) Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation. The Journal of Experimental Medicine 206: 89-97.
51. Hamada H, Garcia-Hernandez MdlL, Reome JB, Misra SK, Strutt TM, et al. (2009) Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge. The Journal of Immunology 182: 3469-3481.